WO2001040804A3 - Clearance of aberrant protein in correlation with disease - Google Patents

Clearance of aberrant protein in correlation with disease Download PDF

Info

Publication number
WO2001040804A3
WO2001040804A3 PCT/NL2000/000887 NL0000887W WO0140804A3 WO 2001040804 A3 WO2001040804 A3 WO 2001040804A3 NL 0000887 W NL0000887 W NL 0000887W WO 0140804 A3 WO0140804 A3 WO 0140804A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
aberrant
age related
protein
misreading
Prior art date
Application number
PCT/NL2000/000887
Other languages
French (fr)
Other versions
WO2001040804A9 (en
WO2001040804A2 (en
Inventor
Elisabeth Maria Hol
Leeuwen Frederik Willem Van
Original Assignee
Konink Nl Akademie Van Wetensc
Elisabeth Maria Hol
Leeuwen Frederik Willem Van
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Konink Nl Akademie Van Wetensc, Elisabeth Maria Hol, Leeuwen Frederik Willem Van filed Critical Konink Nl Akademie Van Wetensc
Priority to AU27156/01A priority Critical patent/AU2715601A/en
Publication of WO2001040804A2 publication Critical patent/WO2001040804A2/en
Publication of WO2001040804A3 publication Critical patent/WO2001040804A3/en
Publication of WO2001040804A9 publication Critical patent/WO2001040804A9/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention provides means and methods for the detection of a disease or pathological condition associated with molecular misreading of coding sequences in the genome and/or associated with the secretion of aberrant protein, comprising providing a sample of a body fluid and/or tissue of a patient and determining a level of a proteins aberrant counterpart in said body fluid and/or tissue. Molecular misreading seems to be a general cause for the synthesis of nonsense transcripts. Previously, molecular misreading was deemed to occur in age related disease and was seen as one of the mechanisms causing age related disease. In the present invention we observed that molecular misreading also occurs in healthy individuals. Surprisingly, the levels of aberrant protein in the body fluids of healthy non demented individuals is higher than in individuals suffering from age related disease. Determining levels of aberrant proteins, such as a +1 protein, allows diagnosing Alzheimers disease in an early stage of this disease, when mild cognitive impairments are apparent in these patients, and allows detecting the effects of any treatment on the disease process.
PCT/NL2000/000887 1999-12-03 2000-12-04 Clearance of aberrant protein in correlation with disease WO2001040804A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU27156/01A AU2715601A (en) 1999-12-03 2000-12-04 Clearance of aberrant protein in correlation with disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99204140.0 1999-12-03
EP99204140 1999-12-03

Publications (3)

Publication Number Publication Date
WO2001040804A2 WO2001040804A2 (en) 2001-06-07
WO2001040804A3 true WO2001040804A3 (en) 2001-12-06
WO2001040804A9 WO2001040804A9 (en) 2002-09-12

Family

ID=8240974

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2000/000887 WO2001040804A2 (en) 1999-12-03 2000-12-04 Clearance of aberrant protein in correlation with disease

Country Status (2)

Country Link
AU (1) AU2715601A (en)
WO (1) WO2001040804A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO314086B1 (en) * 1998-05-08 2003-01-27 Gemvax As Peptides and pharmaceutical compositions containing them, nucleic acid sequences encoding such peptides, plasmids and virus vectors encompassing such DNA sequences and their use for the preparation of pharmaceutical preparations for
EP1887088A1 (en) * 2006-07-20 2008-02-13 Transmedi SA Transcription infidelity, detection and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012992A2 (en) * 1995-10-02 1997-04-10 Royal Netherlands Academy Of Arts And Sciences Diagnosis method for a disease caused by a frameshift mutation in a gene and reagents therefore
WO1998045322A2 (en) * 1997-04-10 1998-10-15 Royal Netherlands Academy Of Arts And Sciences Diagnosis method and reagents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012992A2 (en) * 1995-10-02 1997-04-10 Royal Netherlands Academy Of Arts And Sciences Diagnosis method for a disease caused by a frameshift mutation in a gene and reagents therefore
WO1998045322A2 (en) * 1997-04-10 1998-10-15 Royal Netherlands Academy Of Arts And Sciences Diagnosis method and reagents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D. A. P. EVANS ET AL.: "Frameshift mutations at two hotspots in vasopressin transcripts in post-mitotic neurons.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 91, June 1994 (1994-06-01), WASHINGTON US, pages 6059 - 6063, XP002030376 *
F. W. VAN LEEUWEN ET AL.: "Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients.", SCIENCE., vol. 279, 9 January 1998 (1998-01-09), AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC., US, pages 242 - 247, XP002091677, ISSN: 0036-8075 *
R. SHERRINGTON ET AL.: "Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease.", NATURE, vol. 375, 29 June 1995 (1995-06-29), LONDON GB, pages 754 - 760, XP002030378 *

Also Published As

Publication number Publication date
WO2001040804A9 (en) 2002-09-12
WO2001040804A2 (en) 2001-06-07
AU2715601A (en) 2001-06-12

Similar Documents

Publication Publication Date Title
WO1998045322A3 (en) Diagnosis method and reagents
WO2000035473A3 (en) Methods for detection and use of differentially expressed genes in disease states
DE59705683D1 (en) IMMUNOLOGICAL DETECTION METHOD OF ANTIBODIES TARGETED AGAINST TISSUE TRANSGLUTAMINASE (tTG), USE OF tTG FOR DIAGNOSIS AND THERAPY CONTROL, AND ORAL PHARMACEUTICAL AGENT CONTAINING tTG
WO2004097429A3 (en) Apociii and the treatmentand diagnosis of diabetes
WO2003073910A3 (en) Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples
GB0124145D0 (en) Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
ATE419516T1 (en) MONOCLONAL ANTIBODIES AND CELL SURFACE ANTIGENS FOR DETECTION AND TREATMENT OF SMALL CELL LUNG CANCER (SCLC)
ES2138729T3 (en) DIAGNOSTIC METHODS OF PREECLAMPSIA.
IL138060A (en) Diagnostic methods for detecting cancer
ATE411808T1 (en) FAT BINDING POLYMERS
TR200000181T2 (en) Ligands containing antibodies that act against endocrine cells.
WO2001040804A3 (en) Clearance of aberrant protein in correlation with disease
BRPI0407213A (en) Method of employing marinobufagenin elevation in determining the presence of preeclampsia and related appliances
WO2005011619A3 (en) Lung-expressed polypeptides
WO2004003563A3 (en) Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
ATE498020T1 (en) 5T4 RNA IN PLASMA AND SERUM AS A MARKER FOR NEOPLASTIC DISEASES
DE502005007962D1 (en) SCREENING PROCESS FOR THE EARLY RECOGNITION OF CEREBRAL VASOSPASM
EP1293570A3 (en) Application of aprataxin gene to diagnosis and treatment for early-onset spinocerebellar ataxia (EAOH)
CHOLANGIOPANCREATOGRAPHY J. ENRIQUE DOMſNGUEZ-MUNOZ
WO2023196576A3 (en) Methods and compositions for detecting or treating neurological diseases and hematological malignancies.
Endo et al. Clinical evaluation of mucosal cancer of the esophagus: analysis of 1584 cases of superficial esophageal cancer resected in Japan
AU2001261674A1 (en) Treatment methods using 17906 and uses therefor
WO2005059562A3 (en) Diagnostic and therapeutic use of the human hif3alpha gene and proteins for neurodegenerative diseases
WO2024040225A3 (en) Diagnosis and treatment of acute kidney injury
Jaquinandi et al. Regarding “Reference value of transcutaneous oxygen measurement in diabetic patients compared with nondiabetic patients”

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/6-6/6, DRAWINGS, REPLACED BY NEW PAGES 1/6-6/6; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP